Advair Diskus, Fluticasone/Salmeterol News

BACKGROUND: Little is known about the combination of different medications in chronic obstructive pulmonary disease .

African American patients with asthma treated with Advair Diskus, a combination of the long-acting beta-agonist salmeterol and the inhaled corticosteroid fluticasone propionate, had a lower rate of ...

Main Category: Respiratory / Asthma Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 11 Jun 2008 - 2:00 PDT African American patients with asthma treated with ...

A subset analysis also found that patients treated with the combination of a LABA and an ICS were significantly less likely to experience a severe exacerbation than patients using an ICS alone.

Patients with both asthma and allergic rhinitis, or seasonal allergies, experience significantly better lung function when treated with Advair Diskus as compared with Singulair .

The use of Advair Diskus 500/50 was associated with the lowest number of cardiovascular adverse events compared to other treatment arms in a post-hoc analysis of data from the TOwards a Revolution in COPD ...

A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure .1 ...

“Reducing exacerbations is one of the primary goals of COPD treatment, and this second study presented today shows convincingly that Advair effectively addresses this pressing need”

COPD is a progressive, life-threatening lung disease that includes chronic bronchitis, emphysema or both. via Earth Times

“My goal as a physician is to help reduce the number of exacerbations my patients experience and Advair 250/50 will be a critical treatment in helping meet that goal.”

Main Category: Respiratory / Asthma Also Included In: Infectious Diseases / Bacteria / Viruses ; Regulatory Affairs / Drug Approvals ; Clinical Trials / Drug Trials Article Date: 01 May 2008 - 0:00 PDT The U.S. ... via Medical News Today

Drug maker GlaxoSmithKline PLC said Wednesday government regulators approved expanded usage of its best-selling drug Advair Diskus. via Canadian Business Magazine

“This study is a large step forward in furthering our knowledge of the interplay between genetics and therapy in asthma.”

Data presented by GlaxoSmithKline showed that genetic differences at the site of the beta-2 adrenergic receptor gene in asthma patients did not lead to different responses to Advair Diskus or Serevent Diskus . via EMaxHealth

“These two analyses found that use of Advair was associated with fewer serious outcomes”

Advair Diskus was associated with fewer asthma-related hospitalizations and emergency department visits in pediatric patients when compared to the use of inhaled corticosteroids alone, and use of Advair by ... via Medical News

“These two analyses found that use of Advair was associated with fewer serious outcomes”

Advair Diskus was associated with fewer asthma-related hospitalizations and emergency department visits in pediatric patients when compared to the use of inhaled corticosteroids alone, and use of Advair by ... via Earth Times

On November 18, 2005, FDA alerted health care professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing in some people, ... via Med Ad News